Patent ID: 7547691

Claim:
A compound of Formula I: wherein: R 1 is hydrogen, hydroxy, halo, methylthio, aminosulfonyl, pyrid-2-ylamino, 3-methylaminocarbonylphenyl, —C(O)NR 8 R 9 , —(CH 2 ) 0-1 NHSO 2 R 12 , —CH 2 NHCONHR 13 , —NHC(O)R 14 , or pyrrolidinonyl optionally substituted with ethyloxycarbonyl; R 2 is hydrogen, hydroxy, halo, cyano, (C 1 -C 4 )alkyl, or (C 1 -C 4 )alkoxy; R 3 is hydrogen, halo, or methyl; R 4 is (a) —NR 6 R 7 or (b) aminomethylcyclohexyl, piperidinyl, 2,2,6,6-tetramethylpiperidin-4-yl, 2,2,6,6-tetramethylpiperidin-4-ylethenyl, 4-(C 1 -C 4 )alkylpiperidin-4-yl, or pyrrolidinyl; wherein (b) may be optionally substituted with a substituent selected from the group consisting of (C 2 -C 4 )alkenyl, (C 3 -C 6 )cycloalkyl, C(O)R 10 , and (C 1 -C 4 )alkyl optionally substituted with halo, (C 1 -C 4 )alkoxy, or (C 3 -C 6 )cycloalkyl; R 5 is hydrogen or hydroxy provided that R 5 must be H when n is 1; R 6 is hydrogen or (C 1 -C 4 )alkyl; R 7 is selected from the group consisting of hydrogen, (C 1 -C 4 )alkyl, piperidin-4-yl optionally substituted with (C 1 -C 4 )alkyl, piperidinylcarbonyl optionally substituted with (C 1 -C 4 )alkyl, pyrrolidin-3-yl optionally substituted with (C 1 -C 4 )alkyl, and pyrrolidinylcarbonyl optionally substituted with (C 1 -C 4 )alkyl; alternatively R 6 and R 7 along with the nitrogen to which they are attached form a ring selected from the group consisting of piperazinyl, homopiperazinyl, 4-dimethylaminopiperidin-1-yl, 3-dimethylaminopyrrolidin-1-yl, or hexahydro-pyrrolo[3,4-c]pyrrolyl; wherein the ring may be optionally substituted one time from the group consisting of (C 2 -C 4 )alkenyl, (C 3 -C 6 )cycloalkyl, C(O)R 10 , and one to three (C 1 -C 4 )alkyl substituents optionally substituted with hydroxy; R 8 is hydrogen or (C 1 -C 4 )alkyl; R 9 is hydrogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, (C 3 -C 6 )cycloalkyl, thiazolyl, imidazolyl, pyridyl, phenyl optionally substituted with halo, 2-hydroxy-2-phenyl-ethyl, imidazolylethyl, 6-chloropyrid-3-ylmethyl, or furan-2-yl-(C 1 -C 4 alkyl); alternatively R 8 and R 9 along with the nitrogen to which they are attached form a heterocycle selected from the group consisting of morpholinyl and thiazinyl; R 10 is hydrogen, (C 1 -C 4 )alkyl, or NHR 11 ; R 11 is hydrogen or (C 1 -C 4 )alkyl; R 12 is (C 1 -C 4 )alkyl, trifluoro(C 1 -C 4 )alkyl, benzyl, or (C 3 -C 6 )cycloalkyl; R 13 is (C 1 -C 4 )alkyl, (C 3 -C 6 )cycloalkyl, or benzyl optionally substituted with (C 1 -C 4 )alkyl, halo, or (C 1 -C 4 )alkoxy; R 14 is (C 3 -C 6 )cycloalkyl, piperidinyl, indolylmethyl, or benzyl optionally substituted with 3-dimethylamino-2-hydroxypropoxy; provided that when R 4 is piperidinyl, R 1 is —C(O)NR 8 R 9 ; and n is 1-7 provided that n is 1 only when R 4 is -aminomethylcyclohexyl or 2,2,6,6-tetramethylpiperidin-4-ylethenyl; or a pharmaceutically acceptable salt thereof.